Previous 10 | Next 10 |
The biotech industry is heavily regulated by the federal government and its science watchdog, the Food and Drug Administration (FDA). As a consequence, biotech investors often evaluate a possible investment by looking at the company's pipeline of future assets. Research and development is a...
Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs Global Sustainability Forum PR Newswire SALT LAKE CITY , Aug. 18, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industr...
Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the second quarter, the Baron Discovery Fund was down 22.66% (Institutional Shares), which was 3.41% below the Russell...
Baillie Gifford’s 13F portfolio value decreased from ~$143B to ~$97.51B this quarter. They increased Spotify and Royalty Pharma while decreasing Cloudflare, Petrobras, BeiGene, CBRE Group, Teladoc, and Peloton Interactive. The top three positions are Moderna, Tesla Motors, ...
Recursion Pharmaceuticals press release ( NASDAQ: RXRX ): Q2 GAAP EPS of -$0.38. Revenue of $7.67M (+200.8% Y/Y). For further details see: Recursion Pharmaceuticals GAAP EPS of -$0.38, revenue of $7.67M
Recursion Provides Business Updates and Reports Second Quarter 2022 Financial Results PR Newswire Actively enrolling participants in our Phase 2/3 clinical trial for the potential treatment of progressive NF2 -mutated meningiomas On track to initiate our Phase ...
Recursion ( NASDAQ: RXRX ) on Thursday said the European Commission had granted an orphan drug designation to its inhibitor REC-4881 for the treatment of familial adenomatous polyposis (FAP). FAP is an inherited disorder characterized by the formation of growths called...
Recursion is Granted EU Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis PR Newswire SALT LAKE CITY , July 21, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology compan...
It can be a lot of fun buying stocks trading in the single digits. While there are a lot of bad companies down in the cheap seats, sometimes you can find some amazing bargains. Our roundtable has found three really cool biotech stocks trading under $10 a share. Here's why we like SeaS...
Baillie Gifford’s 13F portfolio value decreased from ~$182B to ~$143B this quarter. They increased Affirm Holdings, Coupang, and Ginkgo Bioworks while reducing Petroleo Brasileiro and First Republic Bank. The top three positions are Tesla Motors, Moderna, and Illumina, and ...
News, Short Squeeze, Breakout and More Instantly...
Recursion Pharmaceuticals Inc. Company Name:
RXRX Stock Symbol:
NASDAQ Market:
Recursion Pharmaceuticals Inc. Website:
2024-07-27 05:41:00 ET Investors looking for stocks that can make dramatic gains often turn toward the biotechnology sector. It isn't unusual for stocks in this industry to shoot higher in response to positive clinical-trial results for experimental new drugs. Recursion Pharmaceutical...
2024-07-13 09:29:00 ET Recursion Pharmaceuticals (NASDAQ: RXRX) is arguably one of the most unique drugmakers on the planet. Though it's classified as a biotech company, its claim to fame is an artificial intelligence (AI)-based approach to speeding up drug discovery and development...
2024-07-11 10:10:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at transformative innovation in biopharma, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmac...